常用連結
1762
中化生
生技醫療業
TWSE
2026-05-29
| 年月 |
當月營收 |
月增率 |
年增率 |
累計營收 |
累計年增率 |
走勢 |
| 2026/04 |
130,981 |
-0.35%
|
+75.98%
|
492,206 |
+84.08%
|
|
| 2026/03 |
131,435,000 |
+27.75%
|
+108.85%
|
361,225 |
+87.21%
|
|
| 2026/02 |
102,881,000 |
-18.93%
|
+161.27%
|
229,790,000 |
+76.73%
|
|
| 2026/01 |
126,909,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2024/12 |
105,604,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2024/11 |
103,605,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2024/10 |
77,116,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2024/09 |
123,658,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2024/08 |
155,812,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2024/07 |
68,710,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2024/06 |
172,265,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2024/05 |
166,657,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2024/04 |
122,236,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2024/03 |
90,707,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2024/02 |
89,301,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2024/01 |
71,704,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2023/12 |
117,627,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2023/11 |
153,828,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2023/10 |
183,897,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2023/09 |
74,242,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2023/08 |
158,641,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2023/07 |
106,273,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2023/06 |
132,165,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2023/05 |
181,028,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2023/04 |
213,290,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2023/03 |
216,908,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2023/02 |
285,652,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 2023/01 |
262,890,000 |
0.00%
|
0.00%
|
— |
0.00%
|
|
| 序 |
持股/單位數分級 |
人數 |
股數/單位數 |
占集保庫存(%) |
比例 |
| 1 |
1-999 |
47,947 |
1,308 |
1.70% |
|
| 2 |
1,000-5,000 |
5,533 |
10,928 |
14.20% |
|
| 3 |
5,001-10,000 |
700 |
5,501 |
7.15% |
|
| 4 |
10,001-15,000 |
188 |
2,418 |
3.14% |
|
| 5 |
15,001-20,000 |
121 |
2,223 |
2.89% |
|
| 6 |
20,001-30,000 |
136 |
3,511 |
4.56% |
|
| 7 |
30,001-40,000 |
62 |
2,244 |
2.91% |
|
| 8 |
40,001-50,000 |
40 |
1,856 |
2.41% |
|
| 9 |
50,001-100,000 |
66 |
4,758 |
6.18% |
|
| 10 |
100,001-200,000 |
34 |
4,657 |
6.05% |
|
| 11 |
200,001-400,000 |
10 |
3,025 |
3.93% |
|
| 12 |
400,001-600,000 |
3 |
1,533 |
1.99% |
|
| 13 |
600,001-800,000 |
3 |
2,162 |
2.81% |
|
| 14 |
800,001-1,000,000 |
2 |
1,803 |
2.34% |
|
| 15 |
1,000,001以上 |
6 |
28,982 |
37.68% |
|
| 公司名稱 | 中化生 |
| 英文簡稱 | CCSB |
| 產業類別 | 生技醫療業 |
| 市場別 | 上市（TWSE） |
| 所屬集團 | — |
| 成立時間 | 1964-05-19 |
| 掛牌日期 | 2010-12-20 |
| 董事長 | 王謝怡貞 |
| 總經理 | 蕭文郁 |
| 發言人 | 陳應祈 |
| 代理發言人 | 王冠傑 |
| 總機電話 | 86843318 |
| 傳真號碼 | 86843202 |
| 電子郵件 | report@ccsb.com.tw |
| 公司網站 |
www.ccsb.com.tw
|
| 公司地址 | 新北市樹林區東興街一號 |
| 股務代理 | 元大證券股份有限公司股務代理部 |
| 簽證會計師 | 資誠聯合會計師事務所 |
| 股本 | 769,180,000 元 |
| 已發行普通股數 | 76,918,000 股 |
| 董監持股比例 | — |
| 市值 | 30.04 億元 |
52 週價格區間
目前位置 89.2%
低 24.20
高 40.85